RxDoctor Payments Data

Isaac Kelly, MD

Urology · Upland, CANPI 1083057525

Payments from drug & device makers

$7,803in general payments, 2019–2025

Across 249 payments — averaging $31.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Coloplast$1K
  • Astellas Pharma US Inc$671
  • Teleflex LLC$541
  • AbbVie$528
  • Sumitomo Pharma America, Inc.$421
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$78810%
  • Travel & lodging$5467%
  • Food & beverage$5,92776%
  • Education$5427%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,803 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$220,706
Medicare patients
499
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide22$319,977
MyrbetriqMirabegron135$118,961
GemtesaVibegron79$80,762
Tamsulosin Hcl609$11,775
Tolterodine Tartrate ErTolterodine Tartrate48$6,533
Mirabegron ErMirabegron12$5,640
Potassium Citrate ErPotassium Citrate32$3,501
Finasteride232$3,377
Methenamine Hippurate34$2,948
Estradiol48$2,883
Desmopressin Acetate14$2,596
Tadalafil20$2,046
NitrofurantoinNitrofurantoin Macrocrystal57$1,540
Testosterone Cypionate17$1,402
Alfuzosin Hcl ErAlfuzosin Hcl53$1,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$671$438,938157 claims
Sumitomo Pharma America, Inc.Gemtesa$421$80,76279 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,324 urology providers in California.

Other urology in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →